Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer
Recruiting now
Conditions studied: Breast Carcinoma, Invasive Breast Carcinoma
In brief
This study assesses changes to the immune cells following hypofractionated radiation-induced DNA damage in breast cancer patients. Radiation therapy may cause immune cells to enter tumors and target cancer cells. The goal of this study is to measure the change in the level of immune cells in the tumor before and after radiation therapy.
Key facts
- Study ID
- NCT05406232
- Run by
- M.D. Anderson Cancer Center
- People needed
- 36
- Starts
- 2023-09-15
- Expected to finish
- 2026-12-31
- Last updated by the study team
- 2026-05-06
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients >= 18 years of age with biopsy proven invasive breast cancer
- Breast cancer that appears to be superficially accessible to a tumor punch biopsy
- Patients thought to derive clinical benefit from palliative RT to the breast/chestwall
- In discussions with the medical oncologist, if clinically reasonable, systemic therapy will be held during RT
You may not qualify if…
- A history of prior radiation to the area requiring radiation for which the attending physician believes reirradiation could not be safely delivered
- Pregnancy
- Active usage of anticoagulant medications that are considered to pose an increased risk of tumor punch biopsies
- Receipt of immunotherapy or chemotherapy 7 days prior to start of RT
Where it is running
- M D Anderson Cancer Center — Houston, Texas, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.